LEPU ScienTech Medical Technology (Shanghai) Co., Ltd.
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. Fundamental Analysis
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. (2291.HK) shows moderate financial fundamentals with a PE ratio of 14.58, profit margin of 45.71%, and ROE of 11.91%. The company generates $0.5B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 71.2/100 based on profitability, valuation, growth, and balance sheet metrics. The B grade reflects solid fundamentals with room for improvement in valuation or growth.
Fundamental Health Score
We analyze 2291.HK's fundamental strength across five key dimensions:
Efficiency Score
Excellent2291.HK demonstrates superior asset utilization.
Valuation Score
Excellent2291.HK trades at attractive valuation levels.
Growth Score
Moderate2291.HK shows steady but slowing expansion.
Financial Health Score
Excellent2291.HK maintains a strong and stable balance sheet.
Profitability Score
Moderate2291.HK maintains healthy but balanced margins.
Key Financial Metrics
Is 2291.HK Expensive or Cheap?
P/E Ratio
2291.HK trades at 14.58 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, 2291.HK's PEG of -5.86 indicates potential undervaluation.
Price to Book
The market values LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. at 1.71 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 17.58 times EBITDA. This signals the market has high growth expectations.
How Well Does 2291.HK Make Money?
Net Profit Margin
For every $100 in sales, LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. keeps $45.71 as profit after all expenses.
Operating Margin
Core operations generate 49.87 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $11.91 in profit for every $100 of shareholder equity.
ROA
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. generates $11.37 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. produces operating cash flow of $59.01M, showing steady but balanced cash generation.
Free Cash Flow
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. produces free cash flow of $22.83M, offering steady but limited capital for shareholder returns and expansion.
FCF Per Share
Each share generates $0.07 in free cash annually.
FCF Yield
2291.HK converts 0.66% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
14.58
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-5.86
vs 25 benchmark
P/B Ratio
Price to book value ratio
1.71
vs 25 benchmark
P/S Ratio
Price to sales ratio
6.67
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.001
vs 25 benchmark
Current Ratio
Current assets to current liabilities
23.54
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.12
vs 25 benchmark
ROA
Return on assets percentage
0.11
vs 25 benchmark
ROCE
Return on capital employed
0.13
vs 25 benchmark
How 2291.HK Stacks Against Its Sector Peers
| Metric | 2291.HK Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 14.58 | 26.49 | Better (Cheaper) |
| ROE | 11.91% | 1280.00% | Weak |
| Net Margin | 45.71% | -41709.00% (disorted) | Strong |
| Debt/Equity | 0.00 | 0.69 | Strong (Low Leverage) |
| Current Ratio | 23.54 | 10.09 | Strong Liquidity |
| ROA | 11.37% | -1504484.00% (disorted) | Strong |
2291.HK outperforms its industry in 5 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews LEPU ScienTech Medical Technology (Shanghai) Co., Ltd.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Cyclical, Value, Infrastructure
EPS CAGR
N/A
Industry Style: Cyclical, Value, Infrastructure
FCF CAGR
N/A
Industry Style: Cyclical, Value, Infrastructure